Neuralink lets paralyzed patients drive wheelchairs with pure thought

For the past two years, watching Neuralink demos felt like watching someone play video games with their mind. Moving a mouse cursor around to play chess or type messages is impressive, but it keeps paralyzed patients trapped behind a computer monitor.

Neuralink posted an update from its PRIME clinical study showing that thought-controlled tech has finally stepped into the physical world. Paralyzed participants can now steer, reverse, and adjust a powered wheelchair using nothing but their neural activity.

Turning thoughts into an analog throttle

Instead of completely reinventing the powered wheelchair, Neuralink bridged the gap with a surprisingly pragmatic setup.

The system runs on the N1 implant, a coin-sized device packed with 1,024 electrodes spread across ultra-thin threads inserted into the motor cortex by a surgical robot. When a patient thinks about moving, those neurons still fire electrical signals, even if the body cannot physically carry out the command.

A machine learning model decodes those firing patterns into an on-screen cursor. A custom app mounted on the chair streams a live video feed of the path ahead. When the patient nudges the cursor up, custom electronics translate that into forward motion; down is reverse, and left or right steers. Pushing the cursor farther out increases the chair's speed.

Crucially, there is a built-in dead-man switch. If the user stops concentrating or relaxes, the cursor drifts back to center, gently bringing the wheelchair to a stop instead of letting it careen off-path.

Minutes to master, and goodbye to hunched joysticks

For participants, the ergonomic difference is massive.

Study participant Alex shared that driving the wheelchair via BCI felt like "second nature" within minutes. More importantly, it freed him from legacy adaptive joysticks, which typically forced him to stay in a strained, hunched-head posture just to navigate.

Neuralink reported that 26 people had received the N1 implant globally as of June 22, with clinical trials expanding into the UK. However, the company made sure to note that the system remains purely investigational and has not yet been cleared by the FDA.

Why it matters

We see this as a pivotal pivot from lab novelty to genuine assistive technology. Giving someone living with severe paralysis the agency to roam a hallway or an outdoor path independently restores basic dignity, which is arguably far more impactful than browsing the web.

Yet the clinical battle lines are sharpening. Rivals like Synchron are pursuing endovascular brain-computer interfaces that slip through blood vessels without drilling open the skull. Neuralink offers dramatically higher signal fidelity thanks to its 1,024 direct cortical electrodes, but patients and doctors will ultimately have to weigh whether that richer control is worth the risks of an invasive craniotomy.